Fig. 1

PIM-1 mRNA expression is increased in AML. The one-way ANOVA analysis shows the significant differences of PIM-1 mRNA expression in AML patients compared with complete remission samples and normal control samples (a) and the significant differences among low risk, intermediate risk and high risk (c). The student’s t test results show PIM-1 mRNA expression is obviously upregulated in FLT3+ AML patients and died patients compared with FLT3− patients and surviving patients (b, d), respectively